(Q39123611)

9 September 2017

Dyslipidemia in systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

9 September 2017

1 reference

1 reference

2

Peter Szodoray

1 reference

9 September 2017

Melinda Zsuzsanna Szabó

series ordinal

1

1 reference

PubMed ID

28168401

9 September 2017

Emese Kiss

series ordinal

3

1 reference

9 September 2017

7 February 2017

1 reference

9 September 2017

1 reference

9 September 2017

65

1 reference

9 September 2017

2

1 reference

9 September 2017

543-550

1 reference

https://scigraph.springernature.com/pub.10.1007/s12026-016-8892-9

9 September 2017

0 references

cites work

Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Cardiovascular disease in autoimmune rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Lupus nephritis and end-stage kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Dyslipidaemia in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Systemic lupus erythematosus and "lupus dyslipoproteinemia".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

The positive correlations of apolipoprotein E with disease activity and related cytokines in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Mechanisms of dyslipoproteinemias in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Tumor necrosis factor in the serum of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Pathophysiology of dyslipidemia in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Risk factors for coronary heart disease in connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Use of atorvastatin in systemic lupus erythematosus in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Therapy with statins in patients with refractory rheumatic diseases: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Dyslipidemia in systemic lupus erythematosus: just another comorbidity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Variations in risk attitude across race, gender, and education

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Do all lupus patients need statins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Statin therapy in lupus-mediated atherogenesis: two birds with one stone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

The effects of exercise on lipid profile in systemic lupus erythematosus and healthy individuals: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8892-9

Hepatic uptake of chylomicron remnants

21 January 2018

1 reference

12 December 2020

Cyclosporine A in the long-term management of systemic lupus erythematosus

1 reference

12 December 2020

Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis

1 reference

12 December 2020

Lipoprotein physiology

1 reference

12 December 2020

Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial

1 reference

12 December 2020

Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Long-Term Survival and Apolipoprotein A1 Level in Chronic Heart Failure: Interaction With Tumor Necrosis Factor α -308 G/A Polymorphism.

1 reference

12 December 2020

Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus

1 reference

12 December 2020

Dyslipoproteinemia in pediatric systemic lupus erythematosus

1 reference

12 December 2020

Lipoprotein disorders in diabetes mellitus

1 reference

12 December 2020

The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB)

1 reference

12 December 2020

Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids

1 reference

12 December 2020

Lupus Atherosclerosis Prevention Study (LAPS)

1 reference

12 December 2020

Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors

1 reference

12 December 2020

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

1 reference

12 December 2020

Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort

1 reference

12 December 2020

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study

1 reference

12 December 2020

Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus

1 reference

12 December 2020

Natural history of hypercholesterolemia in systemic lupus erythematosus

1 reference

12 December 2020

Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus

1 reference

12 December 2020

Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus

1 reference

12 December 2020

Effect of Serum Lipoprotein (a) [Lp(a)] in Menopausal Women.

1 reference

12 December 2020

Epidemiology of systemic lupus erythematosus at the change of the millennium: lessons from the Euro-Lupus and the LUMINA projects

1 reference

12 December 2020

[Analysis of traditional cardiovascular risk factors in patients with systemic lupus erythematosus].

1 reference

12 December 2020

OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement

1 reference

12 December 2020

Role of lipids in the progression of renal disease in systemic lupus erythematosus patients

1 reference

12 December 2020

Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus

1 reference

12 December 2020

Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux

1 reference

12 December 2020

A pravastatin dose-escalation study in systemic lupus erythematosus

1 reference

12 December 2020

Review: The role of paraoxonase in cardiovascular diseases

1 reference

12 December 2020

Chylomicron metabolism is markedly altered in systemic lupus erythematosus

1 reference

12 December 2020

10.1007/S12026-016-8892-9

Identifiers

DOI

1 reference

9 September 2017

1 reference

PubMed ID

28168401